Anti-CD19 Autologous CAR-T Cell therapy (920th Hospital)

N/A

Report date: 2023/07/07 20:01:23

Base Information

Drug NameAnti-CD19 Autologous CAR-T Cell therapy (920th Hospital)

Drug Alias NameOlyCAR-019

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacementsAnti-CD19

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsLymphoma, B-CellLeukemia, B-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaPhase 2 Clinical

Originator CompaniesThe 920th Hospital Of Joint Logistics Support Force Of PLA

China Registration ClassN/A

Develop Information

Active CompaniesThe 920th Hospital Of Joint Logistics Support Force Of PLA

Inactive CompaniesN/A

Active IndicationsLymphoma, B-CellLeukemia, B-Cell

Inactive IndicationsN/A

Other Information

ATC CodeN/A